Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.

Literature DB >> 27591333

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.

Sied Kebir¹, Laurèl Rauschenbach¹, Norbert Galldiks¹, Max Schlaak¹, Elke Hattingen¹, Jennifer Landsberg¹, Ralph A Bundschuh¹, Karl-Josef Langen¹, Björn Scheffler¹, Ulrich Herrlinger¹, Martin Glas².

Abstract

Entities: Chemical Disease

Keywords: FET-PET; brain metastases; melanoma; pseudoprogression.

Mesh：

Substances：

Year: 2016 PMID： 27591333 PMCID： PMC5035529 DOI： 10.1093/neuonc/now154

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

5 in total

1. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Authors: Norbert Galldiks; Veronika Dunkl; Gabriele Stoffels; Markus Hutterer; Marion Rapp; Michael Sabel; Guido Reifenberger; Sied Kebir; Franziska Dorn; Tobias Blau; Ulrich Herrlinger; Peter Hau; Maximilian I Ruge; Martin Kocher; Roland Goldbrunner; Gereon R Fink; Alexander Drzezga; Matthias Schmidt; Karl-Josef Langen
Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-20 Impact factor: 9.236

2. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Authors: F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jeffrey S Weber; Adil Daud; Omid Hamid; Amita Patnaik; Antoni Ribas; Caroline Robert; Tara C Gangadhar; Anthony M Joshua; Peter Hersey; Roxana Dronca; Richard Joseph; Darcy Hille; Dahai Xue; Xiaoyun Nicole Li; S Peter Kang; Scot Ebbinghaus; Andrea Perrone; Jedd D Wolchok
Journal: J Clin Oncol Date: 2016-03-07 Impact factor: 44.544

3. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531

4. Static FET-PET and MR Imaging in Anaplastic Gliomas (WHO III).

Authors: Stefanie Bette; Patrick Peschke; Johannes Kaesmacher; Claire Delbridge; Thomas Pyka; Friederike Schmidt-Graf; Claus Zimmer; Bernhard Meyer; Florian Ringel; Jens Gempt
Journal: World Neurosurg Date: 2016-03-04 Impact factor: 2.104

5. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Authors: Sied Kebir; Rolf Fimmers; Norbert Galldiks; Niklas Schäfer; Frederic Mack; Christina Schaub; Moritz Stuplich; Michael Niessen; Theophilos Tzaridis; Matthias Simon; Gabriele Stoffels; Karl-Josef Langen; Björn Scheffler; Martin Glas; Ulrich Herrlinger
Journal: Clin Cancer Res Date: 2015-12-16 Impact factor: 12.531

5 in total

27 in total

Review 1. Brain metastases: neuroimaging.

Authors: Whitney B Pope
Journal: Handb Clin Neurol Date: 2018

2. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.

Authors: Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson
Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300

3. PET imaging in patients with brain metastasis-report of the RANO/PET group.

Authors: Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn
Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300

4. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.

Authors: Garry Ceccon; Lazaros Lazaridis; Gabriele Stoffels; Marion Rapp; Manuel Weber; Tobias Blau; Phillip Lohmann; Sied Kebir; Ken Herrmann; Gereon R Fink; Karl-Josef Langen; Martin Glas; Norbert Galldiks
Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-21 Impact factor: 9.236

Review 5. Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.

Authors: Enrico Franceschi; Santino Minichillo; Alba A Brandes
Journal: CNS Drugs Date: 2017-08 Impact factor: 5.749

Review 6. [Brain metastases-Interdisciplinary approach towards a personalized treatment].

Authors: S Grau; M Herling; C Mauch; N Galldiks; H Golla; M Schlamann; A H Scheel; E Celik; M Ruge; R Goldbrunner
Journal: Chirurg Date: 2021-01-27 Impact factor: 0.955

7. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Authors: Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen
Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300